MedTrace Logo

Effectiveness of Noninvasive Vagus Stimulation for Upper Extremity in Parkinson's Disease

NCT05456451 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2022-07-13

No results posted yet for this study

Summary

Vagus nerve stimulation in the treatment of PD is a non-pharmacological intervention with the potential to improve gait, cognition, fatigue, and autonomic functions, but more evidence is needed for VSS in the treatment of PD. The potential mechanisms of VSS in the improvement seen in PD are explained by increased cholinergic transmission, decreased neuroinflammation, and enhanced NE release.

In this study, it was aimed to investigate the effects of non-invasive vagus nerve stimulation to be applied to patients with Parkinson's disease on tremor and vagus nerve activity in patients.

The tremor and autonomic activations of the participants will be evaluated at pre and post treatment.

Conditions

  • Parkinson Disease
  • Upper Extremity Dysfunction
  • Tremor

Interventions

DEVICE

noninvasive vagus nerve srimulation

Non-invasive Vagus nerve stimulation (VNS) stimulates the vagus nerve through the ear via a headset. VNS is a non-pharmacological intervention with the potential to improve walking, cognition, fatigue, and autonomic functions in the treatment of Parkinson's disease.

Sponsors & Collaborators

  • Sisli Hamidiye Etfal Training and Research Hospital

    collaborator OTHER

  • Acibadem Atakent University Hospital

    collaborator OTHER

  • Istanbul Physical Medicine Rehabilitation Training and Research Hospital

    collaborator OTHER_GOV

  • Kanuni Sultan Suleyman Training and Research Hospital

    lead OTHER

Principal Investigators

  • E. Efe Is, M.D. · Sisli Hamidiye Etfal Training and Research Hospital

  • Ceyhun Basoglu, M.D. · Acibadem Atakent University Hospital

  • Mustafa Corum, M.D. · Istanbul Physical Medicine and Rehabilitation Training and Research Hospital

  • Ali Veysel Ozden, M.D. · Bahçeşehir University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
40 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-25
Primary Completion
2022-09-25
Completion
2022-10-25

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05456451 on ClinicalTrials.gov